Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial

Read Time:6 Second

Gilead’s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

CEO Kelly Ortberg said a replacement for Ted Colbert would be named later.

The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's...

Nearly half of family offices are expecting double-digit returns this year, according to Citi Private Bank's 2024 Global Family Office...

Carolina Panthers President Kristi Coleman and Las Vegas Raiders President Sandra Douglass Morgan are the only two female presidents out...

American has been working with banks and card networks on a new deal with the aim of consolidating its business...

The company's Slack server was hacked in July, leading to more than a terabyte of company data being leaked to...